SEARCH

検索詳細

相山　健 (アイヤマ　タケシ)

医学研究院　外科系部門　外科学分野特任助教

研究者基本情報

■ 学位
  • 医学博士, 北海道大学, 2021年03月
■ URL
researchmap URLホームページURL■ ID 各種
研究者番号
  • 50908176
J-Global ID■ 研究キーワード・分野
研究キーワード
  • エキノコックス症
  • EB1(MAPRE1)
  • 消化器外科
  • 肝癌
研究分野
  • ライフサイエンス, 寄生虫学, 肝エキノコックス症
  • ライフサイエンス, 消化器外科学, 肝癌

研究活動情報

■ 受賞
  • 2021年10月, IASGO-CME 2021, Best Poster Award
    EB1 promotes proliferation and invasion of hepatocellular carcinoma cells
    相山健
■ 論文
  • Prognostic significance of Albumin-Bilirubin score changes in patients treated with systemic therapy for recurrent hepatocellular carcinoma after liver resection.
    Yoh Asahi; Tatsuhiko Kakisaka; Tatsuya Orimo; Shingo Shimada; Akihisa Nagatsu; Takeshi Aiyama; Sunao Fujiyoshi; Yuzuru Sakamoto; Yuki Fujii; Yuichi Yoshida; Shunsuke Shichi; Ken Imaizumi; Akinobu Taketomi
    Surgery today, 2025年12月24日, ［国内誌］
    英語, 研究論文（学術雑誌）, PURPOSE: To clarify the characteristics of patients who received systemic therapy for recurrent hepatocellular carcinoma after liver resection and evaluate the associated prognostic factors. METHODS: We retrospectively analyzed data from 177 hepatocellular carcinoma patients with recurrence after liver resection; 79 received tyrosine kinase inhibitors or immune checkpoint inhibitors. Prognostic factors were analyzed in the patients who received systemic therapy. RESULTS: The median survival time after the initiation of systemic therapy was 23.3 months among the patients who received such therapy. These patients had more advanced disease at recurrence than those who did not receive systemic therapy. In the systemic therapy group, a deterioration of liver function relative to the preoperative status, expressed as the change in the albumin-bilirubin score (≥ 0.469 vs. <0.469), was independently associated with a poorer survival (9.5 vs. 25.2 months, respectively; P = 0.022). Receiving multiple regimens was associated with a longer survival than receiving a single regimen (36.6 vs. 17.7 months, respectively; P = 0.023). Four patients (5.1%) achieved complete remission, two with systemic therapy alone and two after conversion therapy; all achieved a long-term overall survival. CONCLUSIONS: A preserved liver function and multiple systemic therapy regimens are favorable prognostic factors. Achieving complete remission results in an improved long-term survival.
  • [A Case of Intrahepatic Cholangiocarcinoma Treated with Extended Right Hepatectomy with Partial Resection of the Inferior Vena Cava Following Laparoscopic Portal Vein Ligation].
    Takeshi Aiyama; Tatsuhiko Kakisaka; Yoichi Yamamoto; Shunsuke Shichi; Yuki Fujii; Sunao Fujiyoshi; Akihisa Nagatsu; Norio Kawamura; Masaaki Watanabe; Ryoichi Goto; Akinobu Taketomi
    Gan to kagaku ryoho. Cancer & chemotherapy, 52, 13, 1420, 1422, 2025年12月, ［国内誌］
    日本語, 研究論文（学術雑誌）, INTRODUCTION: Portal vein embolization(PVE)is a preoperative procedure that requires contrast media, making it contraindicated in patients with a history of contrast-induced anaphylaxis. We report a case of intrahepatic cholangiocarcinoma (ICC)in which laparoscopic right portal vein ligation(PVL)was performed as an alternative to PVE due to this contraindication. CASE: A 60-year-old woman was found to have a liver tumor during a health checkup. Further evaluation led to a diagnosis of ICC. The tumor was in close contact with the right and middle hepatic veins and the inferior vena cava(IVC) and showed enlarged hilar and para-aortic lymph nodes(#16b1). Surgery was initially deemed unfeasible at another hospital, and systemic chemotherapy(GEM+CDDP+durvalumab)was initiated, maintaining stable disease for approximately 1 year. She was referred for potential conversion surgery. Although PVE was indicated, it was contraindicated due to a history of contrast anaphylaxis. Therefore, laparoscopic right PVL was performed instead. On postoperative day 26, extended right hepatectomy with partial IVC resection, cholecystectomy, and lymphadenectomy(including #16b1 int & lat)was performed. Aside from autosensitization dermatitis, her postoperative course was uneventful, and she was discharged on day 17. CONCLUSION: Laparoscopic PVL is a safe and effective alternative to PVE in patients with contrast contraindications.
  • Risk Factors and Management of Portal Vein Thrombosis after Hepatectomy: A Single-Center Experience.
    Kazuki Wakizaka; Shunsuke Shichi; Takeshi Aiyama; Yoh Asahi; Akihisa Nagatsu; Tatsuya Orimo; Tatsuhiko Kakisaka; Akinobu Taketomi
    Annals of surgery open : perspectives of surgical history, education, and clinical approaches, 5, 4, e523, 2024年12月, ［国際誌］
    英語, 研究論文（学術雑誌）, OBJECTIVE: This study investigated the risk factors and management of portal vein thrombosis (PVT) after hepatectomy. BACKGROUND: PVT after hepatectomy can cause liver dysfunction and portal hypertension, and may be fatal. However, it has not been sufficiently investigated. METHODS: The study included 1403 consecutive patients who underwent elective hepatectomy at our department from January 2010 to July 2022. The patients were divided into PVT and non-PVT groups based on the presence or absence of PVT, and relevant risk factors were analyzed. The management and prognosis of patients with PVT were investigated. RESULTS: Among the 1403 patients, PVT occurred in 33 cases, giving a frequency of 2.4%. In univariate analyses, female sex (P = 0.03), portal vein reconstruction (P = 0.01), and left lateral sectionectomy (P < 0.001) were significant risk factors for PVT. On multivariate analysis, portal vein reconstruction (P = 0.01) and left lateral segmentectomy (P < 0.001) remained significant risk factors for PVT. The management options for PVT were thrombectomy, antithrombotic therapy, and observation. With antithrombotic therapy, 96.4% of patients achieved PVT resolution. Among patients who underwent hepatectomy with portal vein reconstruction, the PVT site was the main trunk of the portal vein in all 3 cases, and thrombectomy was performed in 2 cases. No perioperative mortality was observed. CONCLUSIONS: In the present study, portal vein reconstruction and left lateral sectionectomy were identified as risk factors for PVT after hepatectomy. As PVT can be fatal, early detection and appropriate treatment according to the status of PVT are important.
  • 分子標的薬がBCLC stage Cの肝細胞癌の手術成績に与えた影響
    旭 よう; 柿坂 達彦; 折茂 達也; 長津 明久; 相山 健; 脇坂 和貴; 志智 俊介; 武冨 紹信
    日本癌治療学会学術集会抄録集, 62回, O16, 5, (一社)日本癌治療学会, 2024年10月
    英語
  • Improved survival outcome of curative liver resection for Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma in the era of tyrosine kinase inhibitors.
    Yoh Asahi; Tatsuhiko Kakisaka; Toshiya Kamiyama; Tatsuya Orimo; Shingo Shimada; Akihisa Nagatsu; Takeshi Aiyama; Yuzuru Sakamoto; Kazuki Wakizaka; Shunsuke Shichi; Hirofumi Kamachi; Akinobu Taketomi
    Hepatology research : the official journal of the Japan Society of Hepatology, 2024年07月26日, ［国際誌］
    英語, 研究論文（学術雑誌）, AIM: This study was undertaken to evaluate the outcome of curative liver resection, (LR) of Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma (BCLC-C HCC) after tyrosine kinase inhibitors (TKIs) became approved as a treatment option for recurrent lesions. METHODS: Sixty-seven patients with BCLC-C HCC who underwent curative LR were enrolled in this study. The patients were classified into two groups according to whether LR was performed before (n = 24) or after (n = 43) TKI approval ("beforeTKI" and "afterTKI" group, respectively). RESULTS: There was no difference in the median disease-free survival time after LR between the beforeTKI and afterTKI groups (5.6 and 7.1 months, respectively; p = 0.435). However, the median survival time after LR was longer in the afterTKI than beforeTKI group (42.7 and 14.9 months, respectively; p = 0.022). Univariate and multivariate analyses showed that the date of LR was the only independent factor affecting postresection survival. When the patients were limited to those with recurrence, there were no differences in the recurrence pattern or progression of HCC at the time of recurrence between the two groups. The only difference in the treatment distribution was the administration of TKIs (14 of 34 patients in afterTKI group and only 1 of 19 patients in beforeTKI group, p < 0.001). CONCLUSION: These data suggest that TKI therapy for recurrent BCLC-C HCC is associated with improved overall survival. Thus, LR could be a promising option for BCLC-C HCC in the current era of TKI therapy.
  • Diacylglycerol kinase alpha is a proliferation marker of intrahepatic cholangiocarcinoma associated with the prognosis.
    Shunsuke Shichi; Ko Sugiyama; Yoh Asahi; Chisato Shirakawa; Hiroki Nakamoto; Saori Kimura; Kazuki Wakizaka; Takeshi Aiyama; Akihisa Nagatsu; Tatsuya Orimo; Tatsuhiko Kakisaka; Akinobu Taketomi
    Cancer medicine, 13, 9, e7238, 2024年05月, ［国際誌］
    英語, 研究論文（学術雑誌）, BACKGROUND: Intrahepatic cholangiocarcinoma (ICC) has a high recurrence rate and a poor prognosis. Thus, the development of effective treatment and prognostic biomarkers is required. High expression of diacylglycerol kinase alpha (DGKα) is a prognostic factor for the recurrence of hepatocellular carcinoma. However, the relationship between DGKα expression and prognosis in ICC has not been reported. METHODS: Immunohistochemistry (IHC) with anti-DGKα antibody was performed on surgical specimens of ICC (n = 69). First, DGKα expression in cancer cells was qualitatively classified into four groups (-, 1+, 2+, 3+) and divided into two groups (DGKα- and DGKα+1 + to 3+). The relationship between clinical features and DGKα expression was analyzed. Second, Ki-67 expression was evaluated as a cell proliferation marker. The number of Ki-67-positive cells was counted, and the relationship with DGKα expression was examined. RESULTS: DGKα IHC divided the patients into a DGKα+ group (1+: n = 15; 2+: n = 5; 3+: n = 5) and a DGKα- group (-: n = 44). In the DGKα+ group, patients were older and had advanced disease. Both overall survival and recurrence-free survival (RFS) were significantly worse in the DGKα+ patients. DGKα+ was identified as an independent prognostic factor for RFS by multivariate analysis. Furthermore, the number of Ki-67-positive cells increased in association with the staining levels of DGKα. CONCLUSION: Pathological DGKα expression in ICC was a cancer proliferation marker associated with recurrence. This suggests that DGKα may be a potential therapeutic target for ICC.
  • 肝内胆管癌における術前リンパ節転移評価およびリンパ節郭清の臨床的意義
    志智 俊介; 脇坂 和貴; 相山 健; 長津 明久; 折茂 達也; 柿坂 達彦; 武冨 紹信
    日本外科学会定期学術集会抄録集, 124回, PS, 1, (一社)日本外科学会, 2024年04月
    日本語
  • 再肝切除症例に対する低侵襲手術の工夫と注意点
    長津 明久; 柿坂 達彦; 志智 俊介; 脇坂 和貴; 相山 健; 折茂 達也; 武冨 紹信
    日本外科学会定期学術集会抄録集, 124回, PS, 6, (一社)日本外科学会, 2024年04月
    日本語
  • 切除不能肝細胞癌に対してアテゾリズマブ・ベバシズマブ併用療法後にconversion surgeryを施行し得た3症例
    小林 正幸; 相山 健; 柿坂 達彦; 折茂 達也; 長津 明久; 脇坂 和貴; 志智 俊介; 清水 亜衣; 大川 紘弥; 武冨 紹信
    日本外科学会定期学術集会抄録集, 124回, PS, 4, (一社)日本外科学会, 2024年04月
    日本語
  • Child-Pugh分類Bの肝細胞癌に対する肝切除術の検討
    脇坂 和貴; 志智 俊介; 相山 健; 長津 明久; 折茂 達也; 柿坂 達彦; 武冨 紹信
    日本外科学会定期学術集会抄録集, 124回, PS, 4, (一社)日本外科学会, 2024年04月
    日本語
  • 当科における胆道癌に対する肝膵同時切除症例の臨床病理学的検討
    柿坂 達彦; 折茂 達也; 長津 明久; 相山 健; 脇坂 和貴; 志智 俊介; 武冨 紹信
    日本外科学会定期学術集会抄録集, 124回, PS, 7, (一社)日本外科学会, 2024年04月
    日本語
  • 術前に肝硬化性血管腫との鑑別に難渋した細胆管細胞癌の1切除例
    森越 健之介; 脇坂 和貴; 志智 俊介; 相山 健; 長津 明久; 折茂 達也; 柿坂 達彦; 武冨 紹信
    日本外科学会定期学術集会抄録集, 124回, RS, 4, (一社)日本外科学会, 2024年04月
    日本語
  • ラットにおけるischemia free liver transplantation法の確立
    藤好 直; 藤好 真人; 山本 葉一; 相山 健; 長津 明久; 川村 典生; 渡辺 正明; 後藤 了一; 柿坂 達彦; 深井 原; 嶋村 剛; 武冨 紹信
    移植, 59, Supplement, s344_2, s344_2, 一般社団法人 日本移植学会, 2024年
    日本語, 緒言：肝移植において、機械灌流法は臨床応用の段階にあり、有効性が報告されている。治療的機械灌流の目的は臓器保存環境の最適化であり、体内外での機械灌流により臓器無灌流状態を排除したischemia free liver transplantation (IFLT)法はその究極的な形態の一つである。この方法はGuangzhouグループにより開発され、臨床研究が行われてきたが、技術的要求が高く、基礎研究モデルは未確立である。我々は、ラットIFLTモデルの開発に成功しており、改良により良好な成績を達成したのでここに報告する。方法：ドナー、レシピエントともWister Rat (250g, オス)を用い、灌流形式は経門脈的冷温酸素化機械灌流とした。ドナー肝血流を維持しながら、脾静脈より灌流カテーテル、肝下部下大静脈より排液カテーテルを挿入し、血流遮断と同時に機械灌流を開始し、機械灌流下に摘出および体外保存を行った。レシピエントの肝全摘後、機械灌流下に肝上部下大静脈と門脈を手縫い吻合し、血流再開と同時に機械灌流を停止した。結果：灌流液を冷温細胞外液、保存時間を短時間 (臓器摘出後すぐにレシピエント手術を開始)としたIFLTにおいて、全例でレシピエントの生存が得られた。考察：IFLTは将来性の高い機械灌流法であり、当モデルはその基礎研究に寄与しうるものと考えられる。
  • Expression of Wnt5a and ROR2, Components of the Noncanonical Wnt-Signaling Pathway, is Associated with Tumor Differentiation in Hepatocellular Carcinoma.
    Kazuki Wakizaka; Toshiya Kamiyama; Tatsuhiko Kakisaka; Tatsuya Orimo; Akihisa Nagatsu; Takeshi Aiyama; Shunsuke Shichi; Akinobu Taketomi
    Annals of surgical oncology, 31, 1, 262, 271, 2024年01月, ［国際誌］
    英語, 研究論文（学術雑誌）, BACKGROUND: Wnt5a is the key ligand of the noncanonical Wnt pathway, and receptor tyrosine kinase-like orphan receptor 2 (ROR2) is a receptor associated with Wnt5a. The association between the noncanonical Wnt-signaling pathway and carcinogenesis in hepatocellular carcinoma (HCC) is unclear. This study investigated the significance of ROR2 expression in HCC. METHODS: The study examined ROR2 expression in liver cancer cell lines. Immunohistochemical staining of ROR2 was performed on 243 resected HCC specimens. The study investigated ROR2 expression and its association with clinicopathologic factors and prognosis. RESULTS: Findings showed that ROR2 was expressed in well-differentiated Huh7 and HepG2 cells, but not in poorly differentiated HLE and HLF cells. Expression of ROR2 was positive in 147 (60.5%) and negative in 96 (39.5%) HCC specimens. A significant association was shown between ROR2 negativity and high alpha-fetoprotein (AFP) level (P = 0.006), poor differentiation (P = 0.015), and Wnt5a negativity (P = 0.024). The 5-year overall survival (OS) rate for the ROR2-negative group (64.2 %) tended to be worse than for the ROR2-positive group (73.8%), but the difference was not significant (P = 0.312). The 5-year OS rate was 78.7% for the ROR2+Wnt5a+ group, 71.3 % for the ROR2+Wnt5a- group, 80.8% for the ROR2-Wnt5a+ group, and 60.5 % for the ROR2-Wnt5a- group. The OS in the ROR2-Wnt5a- group was significantly poorer than in the ROR2+Wnt5a+ group (P = 0.030). The multivariate analysis showed that Wnt5a-ROR2- was an independent prognostic factor (hazard ratio, 2.058; 95% confidence interval, 1.013-4.180; P = 0.045). CONCLUSIONS: The combination of ROR2 and Wnt5a may be a prognostic indicator for HCC. The Wnt5a/ROR2 signal pathway may be involved in the differentiation of HCC. This pathway may be a new therapeutic target for HCC.
  • 【COVID-19のみならず!肝胆膵と感染症】肝胆膵診療での感染症各論 日常臨床における肝エキノコックス症
    相山 健; 柿坂 達彦; 折茂 達也; 長津 明久; 脇坂 和貴; 志智 俊介; 岡田 宏美; 武冨 紹信
    肝胆膵, 87, 3, 287, 294, (株)アークメディア, 2023年09月
    日本語
  • Lymphaticovenous anastomosis for treatment of refractory chylous ascites: A case report.
    Shoichi Tsuzaka; Takeshi Aiyama; Hirofumi Kamachi; Tatsuhiko Kakisaka; Tatsuya Orimo; Akihisa Nagatsu; Yoh Asahi; Taku Maeda; Toshiya Kamiyama; Akinobu Taketomi
    Microsurgery, 43, 6, 606, 610, 2023年09月, ［国際誌］
    英語, Chylous ascites, the leakage of lymphatic fluid into the abdominal cavity caused by lymphatic fluid stasis or lymphatic vessel damage, can be treated by lymphaticovenous anastomosis (LVA). We report rarely performed abdominal LVA to treat a case of refractory ascites possibly caused by ligation of the thoracic duct and pleurodesis in a man aged 60 years requiring weekly ascites drainage. Ligation was abandoned because the leakage site was not determined. The greater omentum (GO) was generally edematous and showed lymphatic effusion by gross appearance, and was considered suitable for LVA. We performed once LVA in the lymphatic vessels and veins of the GO using common microsurgical instrumentation and lateral anastomosis. Lymphatic vessels in the omentum were dilated to 2-3 mm, and LVA was simple. After LVA, GO edema improved. Postoperatively, the patient developed paralytic ileus, which improved within a few days, and the patient was discharged without any increase in ascites after starting to diet. One year post-surgery, there was no recurrence of ascites. LVA at the GO may be effective for the treatment of refractory chylous ascites because of its absorptive lymphatic draining capabilities and large transverse vessels.
  • 肝細胞癌におけるWntシグナル伝達経路受容体ROR2の発現についての検討
    脇坂 和貴; 志智 俊介; 相山 健; 長津 明久; 折茂 達也; 柿坂 達彦; 三橋 智子; 武冨 紹信
    日本消化器外科学会総会, 78回, P100, 6, (一社)日本消化器外科学会, 2023年07月
    日本語
  • 肝切除術後の門脈血栓症に対する治療の検討
    脇坂 和貴; 相山 健; 長津 明久; 折茂 達也; 柿坂 達彦; 武冨 紹信
    日本外科学会定期学術集会抄録集, 123回, DP, 4, (一社)日本外科学会, 2023年04月
    日本語
  • ASO Visual Abstract: Hepatectomy is Beneficial for Select Patients with Multiple Hepatocellular Carcinomas.
    Tatsuya Orimo; Toshiya Kamiyama; Tatsuhiko Kakisaka; Akihisa Nagatsu; Yoh Asahi; Takeshi Aiyama; Hirofumi Kamachi; Akinobu Taketomi
    Annals of surgical oncology, 29, 13, 8448, 8448, 2022年09月30日, ［国際誌］
    英語, 研究論文（学術雑誌）
  • Hepatectomy is Beneficial in Select Patients with Multiple Hepatocellular Carcinomas.
    Tatsuya Orimo; Toshiya Kamiyama; Tatsuhiko Kakisaka; Akihisa Nagatsu; Yoh Asahi; Takeshi Aiyama; Hirofumi Kamachi; Akinobu Taketomi
    Annals of surgical oncology, 29, 13, 8436, 8445, 2022年09月13日, ［国際誌］
    英語, 研究論文（学術雑誌）, BACKGROUND: A single hepatocellular carcinoma (HCC) is a good indication for hepatic resection regardless of tumor size, but the surgical indications for cases with multiple HCCs remain unclear. METHODS: We retrospectively reviewed the outcomes of hepatectomies for Barcelona Clinic Liver Cancer (BCLC) stage 0, A, and B HCCs. We further subclassified stage A and B into A1 (single nodule <5 cm, or three or fewer nodules ≤3 cm), A2 (single nodule 5-10 cm), A3 (single nodule ≥10 cm), B1 (two to three nodules >3 cm), and B2 (four or more nodules). RESULTS: A total of 1088 patients were enrolled, comprising 88 stage 0, 750 stage A (A1: 485; A2: 190; A3: 75), and 250 stage B (B1: 166; B2: 84) cases. The 5-year overall survival (OS) rates for stage 0, A1, A2, A3, B1, and B2 patients were 70.4%, 74.2%, 63.8%, 47.7%, 47.5%, and 31.9%, respectively (p < 0.0001). Significant differences in OS were found between stages A1 and A2 (p = 0.0118), A2 and A3 (p = 0.0013), and B1 and B2 (p = 0.0050), but not between stages A3 and B1 (p = 0.4742). In stage B1 patients, multivariate analysis indicated that Child-Pugh B cirrhosis was the only independent prognostic factor for the OS outcome. CONCLUSIONS: A hepatectomy should be considered for multiple HCCs if the number of tumors is three or fewer, especially in patients with no cirrhosis or in Child-Pugh A cases, because the long-term results are equivalent to those for a single HCC.
  • 肝血管筋脂肪腫の1切除例
    佐々木 貴志; 甲谷 理紗子; 細田 峻一; 吉田 苑永; 得地 祐匡; 久保 彰則; 大原 正嗣; 須田 剛生; 中井 正人; 荘 拓也; 小川 浩司; 坂本 直哉; 相山 健; 武冨 紹信; 岡崎 ななせ; 松野 吉宏
    日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 131回・125回, 40, 40, 日本消化器病学会-北海道支部, 2022年09月
    日本語
  • Conversion surgery after lenvatinib treatment for multiple lung metastases from hepatocellular carcinoma
    Shunji Sano; Yoh Asahi; Toshiya Kamiyama; Tatsuhiko Kakisaka; Tatsuya Orimo; Akihisa Nagatsu; Takeshi Aiyama; Keizo Kazui; Hiroki Shomura; Shinya Ueki; Yuzuru Sakamoto; Chisato Shirakawa; Hirofumi Kamachi; Hirokazu Sugino; Tomoko Mitsuhashi; Akinobu Taketomi
    INTERNATIONAL CANCER CONFERENCE JOURNAL, 2022年08月
    英語, 研究論文（学術雑誌）
  • 分子標的薬時代後のBCLC stage C肝細胞癌の切除後成績の変化
    旭 火華; 神山 俊哉; 柿坂 達彦; 折茂 達也; 長津 明久; 相山 健; 蒲池 浩文; 武冨 紹信
    日本外科学会定期学術集会抄録集, 122回, SF, 5, (一社)日本外科学会, 2022年04月
    日本語
  • Laparoscopic liver resection for liver metastasis of leiomyosarcoma of the thigh: a case report.
    Shoichi Tsuzaka; Yoh Asahi; Toshiya Kamiyama; Tatsuhiko Kakisaka; Tatsuya Orimo; Akihisa Nagatsu; Takeshi Aiyama; Takeyuki Uebayashi; Hirofumi Kamachi; Masatake Matsuoka; Kento Wakabayashi; Takuya Otsuka; Yoshihiro Matsuno; Akinobu Taketomi
    Surgical case reports, 8, 1, 47, 47, 2022年03月21日, ［国際誌］
    英語, 研究論文（学術雑誌）, BACKGROUND: Although there is no established treatment strategy for liver metastasis of leiomyosarcoma, liver resection has been reported to be effective in some cases. However, almost all liver resections performed for liver metastasis of primary leiomyosarcoma are reported to be open resections, and there are few reports of liver resection performed by laparoscopy. Here, we report a case of laparoscopic liver resection for liver metastasis of a leiomyosarcoma in the right thigh. CASE PRESENTATION: An 80-year-old man was diagnosed with leiomyosarcoma of the right thigh with liver metastasis. The primary tumor was first resected, and he was discharged on the 25th postoperative day. Four months after primary tumor resection, a laparoscopic right posterior sectionectomy was performed. There were no postoperative complications, and the patient was discharged on the 11th postoperative day with a histopathological diagnosis of liver metastasis of leiomyosarcoma and negative resection margins. Currently, 9 months have passed since the resection of the primary tumor, and 5 months have passed since the laparoscopic liver resection; there is no recurrence. CONCLUSIONS: The liver metastasis of leiomyosarcoma was successfully removed, with good short-term outcomes after the laparoscopic liver resection. Laparoscopic liver resection seems to be effective for liver metastasis of leiomyosarcoma, which is characterized by a high recurrence rate after surgery. However, more case studies may be necessary to examine the effectiveness and long-term results of laparoscopic liver resection for the treatment of liver metastasis of leiomyosarcoma.
  • 肝細胞癌患者の治癒切除後長期予後における腎機能障害の影響
    坂本 譲; 神山 俊哉; 島田 慎吾; 相山 健; 旭 よう; 長津 明久; 折茂 達也; 柿坂 達彦; 蒲池 浩文; 武冨 紹信
    日本臨床外科学会雑誌, 83, 3, 598, 599, 日本臨床外科学会, 2022年03月
    日本語
  • Preventing Recurrence of Hepatocellular Carcinoma After Curative Hepatectomy With Active Hexose-correlated Compound Derived From Lentinula edodes Mycelia.
    Toshiya Kamiyama; Tatsuya Orimo; Kenji Wakayama; Tatsuhiko Kakisaka; Shingo Shimada; Akihisa Nagatsu; Yoh Asahi; Takeshi Aiyama; Hirofumi Kamachi; Akinobu Taketomi
    Integrative cancer therapies, 21, 15347354211073066, 15347354211073066, 2022年, ［国際誌］
    英語, 研究論文（学術雑誌）, PURPOSE: Active hexose-correlated compound (AHCC), a standardized extract of cultured Lentinula edodes mycelia, exerts antitumor effects through anti-inflammatory and immune-modulatory functions. Adjuvant therapy for patients with hepatocellular carcinoma (HCC) who have undergone curative hepatectomy has not been established. The purpose of this study was to evaluate the efficacy and safety of AHCC as adjuvant therapy in patients with advanced HCC after curative hepatectomy. PATIENTS AND METHODS: The study design was single-armed, non-randomized, open (no one was blinded), and uncontrolled. Patients with HCC who underwent curative hepatectomy were treated with AHCC (1 g) 3 times daily orally for 2 years. The inclusion criteria were HCC diagnosed preoperatively as stages A and B of the Barcelona clinic liver cancer (BCLC) classification and alpha-fetoprotein × protein induced by vitamin K absence or antagonist II (PIVKA-II) ≥ 105 for stage A. RESULTS: A total of 29 patients were treated with AHCC, of which 25 (4 patients discontinued) were followed up. The 2-year recurrence-free survival rate after resection was 48% for those without discontinuations and 55.2% for all patients with a history of treatment. Serum albumin levels decreased to a minimum in the first postoperative month and gradually recovered to the preoperative level at 6 months. Almost no change in lymphocyte percentage was observed during follow-up. Inflammation-based prognostic scores were maintained at favorable levels after hepatectomy. Toxicity and adverse events were not observed in any patient. CONCLUSION: AHCC may be safe and effective in preventing HCC recurrence after curative hepatectomy, and further randomized trials of AHCC for its use in this setting are warranted.This clinical trial was registered in UMIN Clinical Trials Registry (ID UMIN000024396).
  • 早期肝細胞癌に対する腹腔鏡下肝部分切除術の治療成績
    旭 よう; 神山 俊哉; 柿坂 達彦; 折茂 達也; 長津 明久; 相山 健; 蒲池 浩文; 武冨 紹信
    日本内視鏡外科学会雑誌, 26, 7, MO084, 6, (一社)日本内視鏡外科学会, 2021年12月
    日本語
  • Outcomes of reduction hepatectomy combined with postoperative multidisciplinary therapy for advanced hepatocellular carcinoma.
    Yoh Asahi; Toshiya Kamiyama; Tatsuhiko Kakisaka; Tatsuya Orimo; Shingo Shimada; Akihisa Nagatsu; Takeshi Aiyama; Yuzuru Sakamoto; Hirofumi Kamachi; Akinobu Taketomi
    World journal of gastrointestinal surgery, 13, 10, 1245, 1257, 2021年10月27日, ［国際誌］
    英語, 研究論文（学術雑誌）, BACKGROUND: The prognosis of advanced hepatocellular carcinoma (HCC) that is not indicated for curative hepatectomy remains poor, despite advances in the treatment of HCC, including the development of tyrosine kinase inhibitors (TKIs). The outcomes of reduction hepatectomy and multidisciplinary postoperative treatment for advanced HCC that is not indicated for curative hepatectomy, including those of recently treated cases, should be investigated. AIM: To examine the outcomes of combination treatment with reduction hepatectomy and multidisciplinary postoperative treatment for advanced HCC that is not indicated for curative hepatectomy. METHODS: Thirty cases of advanced HCC that were not indicated for curative hepatectomy, in which reduction hepatectomy was performed between 2000 and 2018 at the Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, were divided into postoperative complete remission (POCR) (+) and POCR (-) groups, depending on whether POCR of all evaluable lesions was achieved through postoperative treatment. The cases in the POCR (-) group were subdivided into POCR (-) TKI (+) and POCR (-) TKI (-) groups, depending on whether TKIs were administered postoperatively. RESULTS: The 5-year overall survival rate and mean survival time (MST) after reduction hepatectomy were 15.7% and 28.40 mo, respectively, for all cases; 37.5% and 56.55 mo, respectively, in the POCR (+) group; and 6.3% and 14.84 mo, respectively, in the POCR (-) group (P = 0.0041). Tumor size, major vascular invasion, and the number of tumors in the remnant liver after the reduction hepatectomy were also found to be related to survival outcomes. The number of tumors in the remnant liver was the only factor that differed significantly between the POCR (+) and POCR (-) groups, and POCR was achieved significantly more frequently when ≤ 3 tumors remained in the remnant liver (P = 0.0025). The MST was 33.52 mo in the POCR (-) TKI (+) group, which was superior to the MST of 10.74 mo seen in the POCR (-) TKI (-) group (P = 0.0473). CONCLUSION: Reduction hepatectomy combined with multidisciplinary postoperative treatment for unresectable advanced HCC that was not indicated for curative hepatectomy was effective when POCR was achieved via multidisciplinary postoperative therapy. To achieve POCR, reduction hepatectomy should aim to ensure that ≤ 3 tumors remain in the remnant liver. Even in cases in which POCR is not achieved, combined treatment with reduction hepatectomy and multidisciplinary therapy can improve survival outcomes when TKIs are administered.
  • 肝細胞癌に対する最新の集学的治療 術後再発肝細胞癌に対する分子標的薬使用の意義
    旭 よう; 神山 俊哉; 折茂 達也; 柿坂 達彦; 長津 明久; 相山 健; 蒲池 浩文; 武冨 紹信
    日本臨床外科学会雑誌, 82, 増刊, S280, S280, 日本臨床外科学会, 2021年10月
    日本語
  • ハイリスク症例への大腸手術-いかに安全に行うか- 腹腔鏡下大腸切除における心血管塞栓性合併症の発症リスクに関する検討
    市川 伸樹; 本間 重紀; 舩越 徹; 大渕 佳祐; 大島 隆弘; 植村 一仁; 今 裕史; 大野 陽介; 横田 良一; 数井 啓蔵; 石川 隆壽; 水上 達三; 三野 和宏; 前田 好章; 吉田 雅; 下國 達志; 相山 健; 小野 仁; 森田 恒彦; 武冨 紹信
    日本外科学会定期学術集会抄録集, 121回, WS, 2, (一社)日本外科学会, 2021年04月
    日本語
  • ハイリスク症例への大腸手術-いかに安全に行うか- 腹腔鏡下大腸切除における心血管塞栓性合併症の発症リスクに関する検討
    市川 伸樹; 本間 重紀; 舩越 徹; 大渕 佳祐; 大島 隆弘; 植村 一仁; 今 裕史; 大野 陽介; 横田 良一; 数井 啓蔵; 石川 隆壽; 水上 達三; 三野 和宏; 前田 好章; 吉田 雅; 下國 達志; 相山 健; 小野 仁; 森田 恒彦; 武冨 紹信
    日本外科学会定期学術集会抄録集, 121回, WS, 2, (一社)日本外科学会, 2021年04月
    日本語
  • Small Bowel Obstruction Caused by Ileal Endometriosis with Appendiceal and Lymph Node Involvement Treated with Single-Incision Laparoscopic Surgery: A Case Report and Review of the Literature.
    Ryota Koyama; Takeshi Aiyama; Ryoji Yokoyama; Shiro Nakano
    The American journal of case reports, 22, e930141, 2021年03月23日, ［国際誌］
    英語, 研究論文（学術雑誌）, BACKGROUND Endometriosis is an ectopic proliferation of endometrial glands and interstitium outside the uterus. It usually affects the organs surrounding the uterus, and less often, involvement of extrapelvic organs, such as the intestines and urinary tract, is observed. CASE REPORT A 40-year-old woman had been experiencing intermittent right lower abdominal pain for years, which worsened months earlier. The patient was admitted for the worst pain ever accompanying nausea and vomiting. Contrast-enhanced computed tomography revealed a heterogeneously enhanced lesion that measured approximately 50×25×35 mm, and a caliber change of the ileum at the same site with dilated small bowel proximal to the caliber change were observed. Colonoscopy revealed that the ileocecal valve and the lumen of the terminal ileum protruded inward, suggesting an extramural compression by the lesion. Since the patient showed no improvement following conservative therapy, bowel resection through a single-incision laparoscopic surgery was successfully performed. Histopathological exploration showed patchy infiltration of endometrium-like tissues in the muscularis propria and subserosa layers of the ileum and appendix. Moreover, nearby lymph nodes resected for their firmness showed similar findings. CONCLUSIONS We report a case of recurrent intestinal obstruction due to ileal and appendiceal endometriosis with lymph node involvement, which was successfully treated by single-incision laparoscopic surgery. Careful follow-up is important because the prognosis for the intestinal endometriosis with lymph node involvement is still unclear.
  • Analysis of the correlation between alterations in N‑glycans and invasiveness in liver cancer cell lines
    Hidenori Takahashi; Toshiya Kamiyama; Nozomi Hirane; Nozomi Kobayashi; Takeshi Aiyama; Akihisa Nagatsu; Shingo Shimada; Tatsuya Orimo; Tatsuhiko Kakisaka; Moto Fukai; Hideki Yokoo; Hirofumi Kamachi; Shin‑Ichiro Nishimura; Akinobu Taketomi
    Oncology Reports, Spandidos Publications, 2020年10月08日
    研究論文（学術雑誌）
  • Adenomatous polyposis coli-binding protein end-binding 1 promotes hepatocellular carcinoma growth and metastasis
    Takeshi Aiyama; Tatsuya Orimo; Hideki Yokoo; Takanori Ohata; Kanako C. Hatanaka; Yutaka Hatanaka; Moto Fukai; Toshiya Kamiyama; Akinobu Taketomi
    PLOS ONE, 15, 9, e0239462, e0239462, Public Library of Science (PLoS), 2020年09月21日, ［査読有り］, ［筆頭著者］, ［国際誌］
    英語, 研究論文（学術雑誌）, This study was performed to determine the clinical significance of adenomatous polyposis coli (APC)-binding protein end-binding 1 (EB1) in hepatocellular carcinoma (HCC) and to characterize its biochemical role in comparison with previous reports. We performed immunohistochemical staining to detect EB1 expression in tissues from 235 patients with HCC and investigated its correlations with clinicopathological features and prognosis. We also investigated the roles of EB1 in cell proliferation, migration, and tumorigenesis in vitro and in vivo by siRNA- and CRISPR/Cas9-mediated modulation of EB1 expression in human HCC cell lines. The results showed that EB1 expression was significantly correlated with several important factors associated with tumor malignancy, including histological differentiation, portal vein invasion status, and intrahepatic metastasis. Patients with high EB1 expression in HCC tissue had poorer overall survival and higher recurrence rates than patients with low EB1 expression. EB1 knockdown and knockout in HCC cells reduced cell proliferation, migration, and invasion in vitro and inhibited tumor growth in vivo. Further, genes encoding Dlk1, HAMP, and SLCO1B3 that were differentially expressed in association with EB1 were identified using RNA microarray analysis. In conclusion, elevated expression of EB1 promotes tumor growth and metastasis of HCC. EB1 may serve as a new biomarker for HCC, and genes coexpressed with EB1 may represent potential targets for therapy.

    ダウンロード
  • Impact of technically qualified surgeons on laparoscopic colorectal resection outcomes: results of a propensity score‐matching analysis
    N. Ichikawa; S. Homma; T. Funakoshi; T. Ohshima; K. Hirose; K. Yamada; H. Nakamoto; K. Kazui; R. Yokota; T. Honma; Y. Maeda; T. Yoshida; T. Ishikawa; H. Iijima; T. Aiyama; A. Taketomi
    BJS Open, 4, 3, 486, 498, Oxford University Press (OUP), 2020年06月
    研究論文（学術雑誌）
  • Fatty acid-binding protein 5 function in hepatocellular carcinoma through induction of epithelial-mesenchymal transition.
    Takanori Ohata; Hideki Yokoo; Toshiya Kamiyama; Moto Fukai; Takeshi Aiyama; Yutaka Hatanaka; Kanako Hatanaka; Kenji Wakayama; Tatsuya Orimo; Tatsuhiko Kakisaka; Nozomi Kobayashi; Yoshihiro Matsuno; Akinobu Taketomi
    Cancer medicine, 6, 5, 1049, 1061, 2017年05月, ［国際誌］
    英語, 研究論文（学術雑誌）, Hepatocellular carcinoma (HCC) is a highly prevalent cancer with poor prognosis. The correlation between overexpression of fatty acid-binding protein 5 (FABP5) and malignant potential of tumor growth and metastasis in several cancers has been previously reported. However, the correlation between FABP5 expression and HCC malignant behavior remains unknown. We compared FABP5 expression and patient characteristics in paired HCC and adjacent noncancerous liver tissues from 243 patients who underwent surgical resection of primary HCC. Cell proliferation, invasion, and migration assays were performed in HCC cell lines overexpressing FABP5 or downregulated for FABP5. Tumor growths were monitored in xenograft model, and liver and lung metastasis models were established. In the 243 HCC patients, FABP5-positive staining (n = 139/243, 57.2%) was associated with poor prognosis and recurrence (P < 0.0001) and showed positive correlation with distant metastasis, tumor size and vascular invasion (P < 0.05). Cell proliferation, invasion, and migration in vitro were enhanced by upregulation of FABP5 and decreased by downregulation of FABP5 in HCC cell lines. Similar results in tumor formation and metastasis were obtained through in vivo analyses. PCR array results revealed upregulation of SNAI1 in FABP5-overexpressing HepG2 cells. Western blot analysis showed significantly increased expression of E-cadherin and ZO-1 and decreased SNAI1 expression and nuclear translocation of β-catenin by knockdown of FABP5. We revealed a significant role for FABP5 in HCC progression and metastasis through the induction of epithelial-to-mesenchymal transition. FABP5 may be a potential novel prognostic biomarker and new therapeutic target for HCC.
  • 肝細胞癌におけるAdenomatous polyposis coli結合蛋白EB1の機能解析
    相山 健; 横尾 英樹; 折茂 達也; 大畑 多嘉宣; 畑中 佳奈子; 畑中 豊; 松野 吉宏; 福原 崇介; 高橋 秀徳; 若山 顕治; 敦賀 陽介; 蒲池 浩文; 神山 俊哉; 武冨 紹信
    日本外科学会定期学術集会抄録集, 116回, PS, 1, (一社)日本外科学会, 2016年04月
    日本語
  • 肝癌細胞株におけるuPAの発現変化に伴う浸潤能変化と糖鎖異常解析
    高橋 秀徳; 柿坂 達彦; 神山 俊哉; 相山 健; 島田 慎吾; 若山 顕治; 折茂 達也; 敦賀 陽介; 蒲池 浩文; 横尾 英樹; 西村 紳一郎; 武冨 紹信
    日本外科学会定期学術集会抄録集, 116回, OP, 1, (一社)日本外科学会, 2016年04月
    日本語
  • Vp3,4肝細胞癌の門脈腫瘍栓に対する術前放射線治療とAPC-binding protein EB1の発現の意義
    相山 健; 折茂 達也; 横尾 英樹; 大畑 多嘉宣; 畑中 佳奈子; 畑中 豊; 松野 吉宏; 神山 俊哉; 武冨 紹信
    日本癌学会総会記事, 74回, P, 1331, 日本癌学会, 2015年10月
    英語
  • 肝胆膵 肝細胞癌における癌幹細胞マーカーCD44およびCD133発現の意義
    高橋 秀徳; 相山 健; 神山 俊哉; 佐々木 彩実; 畑中 佳奈子; 松野 吉宏; 大畑 多嘉宣; 若山 顕治; 折茂 達也; 柿坂 達彦; 敦賀 陽介; 蒲池 浩文; 横尾 英樹; 武冨 紹信
    日本外科学会定期学術集会抄録集, 115回, OP, 4, (一社)日本外科学会, 2015年04月
    日本語
  • 肝胆膵 肝細胞癌におけるAdenomatous polyposis coli結合蛋白EB1の新規バイオマーカーとしての可能性
    相山 健; 横尾 英樹; 折茂 達也; 大畑 多嘉宣; 畑中 佳奈子; 畑中 豊; 松野 吉宏; 高橋 秀徳; 若山 顕治; 柿坂 達彦; 敦賀 陽介; 蒲池 浩文; 神山 俊哉; 武冨 紹信
    日本外科学会定期学術集会抄録集, 115回, OP, 1, (一社)日本外科学会, 2015年04月
    日本語
  • 肝細胞癌におけるAPC-binding protein EB1の予後・再発予測因子としての有用性(APC-binding protein EB1 is an important predictive factor for the prognosis and recurrence in hepatocellular carcinoma)
    相山 健; 折茂 達也; 横尾 英樹; 大畑 多嘉宣; 畑中 佳奈子; 畑中 豊; 松野 吉宏; 神山 俊哉; 武冨 紹信
    日本癌学会総会記事, 73回, P, 2310, 日本癌学会, 2014年09月
    英語
  • Clear cell sarcoma of the esophagus: report of a case.
    Daisuke Ishii; Mitsuhiro Inagaki; Tatsuya Shonaka; Hiromitsu Akabane; Naoyuki Yanagida; Hiroki Shomura; Tatsuya Orimo; Takeshi Aiyama; Keisuke Sato; Shiro Nakano
    Clinical journal of gastroenterology, 7, 3, 228, 32, 2014年06月, ［国内誌］
    英語, 研究論文（学術雑誌）, We report a rare case of clear cell sarcoma of the esophagus and review the literature regarding clear cell sarcomas of the gastrointestinal tract. A 57-year-old male was admitted with dysphagia during swallowing. Preoperative imaging studies, including upper gastrointestinal endoscopy and endoscopic ultrasonography, showed that the tumor was located between the mucosa and the muscularis propria of the lower esophagus. We performed subtotal esophagectomy with gastric tube reconstruction. Pathological findings of the tumor showed mixed spindle cells and oval cells. Immunohistochemical staining showed that the tumor cells were positive for S-100, vimentin and neuron-specific enolase and negative for α-smooth muscle actin, myoglobin and c-kit. Fluorescence in situ hybridization using a Ewing sarcoma breakpoint region 1 probe showed split signals in a small percentage of cells. We finally diagnosed the patient with clear cell sarcoma of the esophagus.
  • Middle Segment-Preserving Pancreatectomy for Recurrent Metastasis of Renal Cell Carcinoma after Pancreatoduodenectomy: A Case Report
    Aiyama Takeshi; Inagaki Mitsuhiro; Akabane Hiromitsu; Yanagida Naoyuki; Shibaki Taiichiro; Shomura Hiroki; Kudo Takeaki; Shonaka Tatsuya; Oikawa Futoshi; Sakurai Hiroharu; Nakano Shiro
    Case Reports in Surgery, 2014, 1, 3, Hindawi Limited, 2014年, ［査読有り］, ［筆頭著者］, ［国際誌］
    英語, 研究論文（学術雑誌）, Many cases of surgical resection of metastatic pancreatic tumors originating from renal cell carcinoma have been reported; however, cases of reresection of recurrent pancreatic metastasis of renal cell carcinoma in the remnant pancreas are rare. We performed a second resection for recurrent pancreatic metastasis of renal cell carcinoma six years after pancreatoduodenectomy with pancreaticogastrostomy reconstruction. By performing middle segment-preserving pancreatectomy, we were able to successfully spare the exocrine and endocrine pancreatic function compared to that observed after total pancreatectomy, with no signs of recurrence for two years after the surgery.

    ダウンロード
  • 肝細胞癌肺転移切除後19年間無再発の一例
    相山 健; 神山 俊哉; 横尾 英樹; 柿坂 達彦; 折茂 達也; 若山 顕治; 敦賀 陽介; 蒲池 浩文; 武富 紹信
    日本癌治療学会誌, 48, 3, 2409, 2409, (一社)日本癌治療学会, 2013年09月
    日本語
  • 胆石性イレウスの1例
    相山 健; 中野 詩朗; 赤羽 弘充; 稲垣 光裕; 柳田 尚之; 芝木 泰一郎; 正村 裕紀; 庄中 達也; 折茂 達也; 辻 健志
    北海道外科雑誌, 58, 1, 58, 59, 北海道外科学会, 2013年06月
    日本語
  • 高齢者進行再発大腸癌に対するFOLFOX/FOLFIRI療法の治療経験
    正村 裕紀; 中野 詩朗; 赤羽 弘充; 稲垣 光裕; 柳田 尚之; 芝木 泰一郎; 庄中 達也; 折茂 達也; 相山 健; 辻 健志
    日本大腸肛門病学会雑誌, 66, 4, 284, 284, (一社)日本大腸肛門病学会, 2013年04月
    日本語
  • [Prognostic factors affecting the surgical treatment of metastatic lung tumor from colorectal cancer].
    Yoshimi Otani; Hiroki Shomura; Takeshi Aiyama; Tetsuo Funai; Takeshi Tsuji; Tatsuya Orimo; Tatsuya Shonaka; Taiichiro Shibaki; Naoyuki Yanagida; Mitsuhiro Inagaki; Hiromitsu Akabane; Shiro Nakano
    Kyobu geka. The Japanese journal of thoracic surgery, 66, 4, 279, 83, 2013年04月, ［国内誌］
    日本語, 研究論文（学術雑誌）, For aging, people having malignant disease are increasing. And surgical resection is an important part in the treatment of pulmonary metastasis from colorectal cancer. We analyzed the treatment outcome and prognostic factors affecting survival in our subset of patients. We have experienced 64 operations of metastatic lung tumors from colorectal cancer for 23 years since January 1988. Various factors affecting prognosis are studied based on 5-year survival in this report. Overall 5-year survival rate was 38.7%. The disease-free intervals more than 2 years, a solitary metastatic pulmonary lesion and the serum level of prethoracotomy carcinoembryonic antigen (CEA) were significantly affecting factors on the prognosis. Furthermore, sequential study for 23 years couldn't demonstrate the prognostic improvement by the advance of the thoracoscopic technology or the development of the new anti-cancer drugs, though the treatment of patients with pulmonary metastases from colorectal cancer continues to evolve. The role of pulmonary metastasectomy is very important to reduce the volume of metastatic lesions for the better prognosis.
  • 転移性肺腫瘍の治療戦略 反復切除の適応と術式選択 大腸癌肺転移に対する反復切除の有用性についての検討
    正村 裕紀; 船井 哲雄; 大谷 嘉己; 中野 詩朗; 赤羽 弘充; 稲垣 光裕; 柳田 尚之; 芝木 泰一郎; 庄中 達也; 折茂 達也; 相山 健; 辻 健志
    日本外科学会雑誌, 114, 臨増2, 287, 287, (一社)日本外科学会, 2013年03月
    日本語
  • 大腸癌腹膜播種症例の治療成績
    正村 裕紀; 中野 詩朗; 稲垣 光裕; 赤羽 弘充; 柳田 尚之; 芝木 泰一郎; 工藤 岳秋; 庄中 達也; 折茂 達也; 及川 太; 相山 健
    日本大腸肛門病学会雑誌, 66, 2, 129, 129, (一社)日本大腸肛門病学会, 2013年02月
    日本語
  • 閉鎖孔ヘルニアを合併し診断に難渋した膀胱留置カテーテルの膀胱穿孔による麻痺性腸閉塞の1例
    相山 健; 中野 詩朗; 赤羽 弘充; 稲垣 光裕; 柳田 尚之; 芝木 泰一郎; 正村 裕紀; 庄中 達也; 折茂 達也; 辻 健志
    日本腹部救急医学会雑誌, 33, 2, 414, 414, (一社)日本腹部救急医学会, 2013年02月
    日本語
  • 胆石性イレウスの1例
    相山 健; 中野 詩朗; 稲垣 光裕; 赤羽 弘充; 柳田 尚之; 正村 裕紀; 庄中 達也; 折茂 達也; 辻 健志; 芝木 泰一郎
    旭川厚生病院医誌, 22, 2, 71, 74, 旭川厚生病院, 2012年12月
    日本語
  • Bevacizumabの使用経験
    相山 健; 中野 詩朗; 赤羽 弘充; 稲垣 光裕; 柳田 尚之; 芝木 泰太郎; 正村 裕紀; 庄中 達也; 折茂 達也; 辻 健志
    日本癌治療学会誌, 47, 3, 2338, 2338, (一社)日本癌治療学会, 2012年10月
    日本語
  • 大腸癌肝転移に対するPerflubutane(ソナゾイド)による術中造影超音波の有用性
    庄中 達也; 中野 詩朗; 稲垣 光裕; 赤羽 弘充; 柳田 尚之; 正村 裕紀; 折茂 達也; 及川 太; 相山 健; 脇坂 和貴; 芝木 泰一郎
    日本消化器外科学会雑誌, 45, Suppl.2, 154, 154, (一社)日本消化器外科学会, 2012年10月
    日本語
  • Pancreatoduodenectomy for circumportal pancreas accompanying the retroportal pancreatic duct: a case report and review of the literature.
    Tatsuya Shonaka; Mitsuhiro Inagaki; Hiromitsu Akabane; Naoyuki Yanagida; Hiroki Shomura; Takeaki Kudo; Tatsuya Orimo; Futoshi Oikawa; Takeshi Aiyama; Nobuyuki Yanagawa; Kensuke Oikawa; Shiro Nakano
    Clinical journal of gastroenterology, 5, 5, 332, 5, 2012年10月, ［国内誌］
    英語, 研究論文（学術雑誌）, Circumportal pancreas (CP) is an extremely rare pancreatic fusion anomaly which is usually asymptomatic. This report presents the case of a patient with a tumor in the head of a CP and the retroportal accessory pancreatic duct in the pancreatic tissue behind the portal vein. A 53-year-old male was diagnosed with a nonfunctioning neuroendocrine tumor of the pancreas and resection of the tumor was scheduled. The patient was revealed to have CP on preoperative computed tomography and endoscopic retrograde cholangiopancreatography, which showed the pancreatic tissue encircling the portal vein and the retroportal accessory pancreatic duct. The patient safely underwent pylorus-preserving pancreatoduodenectomy reconstructed with pancreaticogastrostomy.
  • 高齢者(80歳以上)大腸癌に対する腹腔鏡下手術の安全性の検討
    相山 健; 中野 詩朗; 稲垣 光裕; 赤羽 弘充; 柳田 尚之; 芝木 泰一郎; 庄中 達也; 折茂 達也; 及川 太; 脇坂 和貴
    日本消化器外科学会総会, 67回, 1, 1, (一社)日本消化器外科学会, 2012年07月
    日本語
  • 十二指腸GISTの1切除例
    庄中 達也; 稲垣 光裕; 中野 詩朗; 赤羽 弘充; 柳田 尚之; 正村 裕紀; 工藤 岳秋; 折茂 達也; 及川 太; 相山 健; 芝木 泰一郎; 櫻井 宏治; 及川 賢輔
    日本臨床外科学会雑誌, 73, 6, 1597, 1597, 日本臨床外科学会, 2012年06月
    日本語
  • 腎癌膵転移膵頭十二指腸切除後の膵内再発に対し尾側切除により膵体部を温存しえた1例
    相山 健; 中野 詩朗; 赤羽 弘充; 稲垣 光裕; 柳田 尚之; 芝木 泰一郎; 正村 裕紀; 庄中 達也; 折茂 達也; 及川 太; 工藤 岳秋
    北海道外科雑誌, 57, 1, 76, 76, 北海道外科学会, 2012年06月
    日本語
  • 旭川厚生病院における肝エキノコックス症手術症例に関する画像及び血清診断を用いた術後経過とその評価
    赤羽 弘充; 中野 詩朗; 稲垣 光裕; 柳田 尚之; 正村 裕紀; 工藤 岳秋; 庄中 達也; 折茂 達也; 及川 太; 相山 健; 芝木 泰一郎; 迫 康仁; 伊藤 園予; 伊藤 亮
    北海道農村医学会雑誌, 44, 38, 44, 北海道農村医学会, 2012年03月
    日本語, 血清学的検査で肝エキノコックス症と確定診断され切除術を受けた64歳女性例について、エキノコックス抗体価とCT像の経時的変化を術後5年間観察した。その結果、抗体は術後6ヵ月までに陰転化し、以後まったく検出されなかった。術前のCTで認めていた嚢胞性病変は術後5年時には認めなかった。
  • 術前画像診断でIPMNを疑った非機能性膵神経内分泌細胞腫瘍の1例
    工藤 岳秋; 中野 詩朗; 稲垣 光裕; 赤羽 弘充; 柳田 尚之; 正村 裕紀; 庄中 達也; 折茂 達也; 及川 太; 相山 健; 芝木 泰一郎
    北海道外科雑誌, 56, 2, 153, 154, 北海道外科学会, 2011年12月
    日本語
  • 脾原発EBV関連炎症性偽腫瘍様濾胞樹状細胞性腫瘍の1例
    相山 健; 中野 詩朗; 赤羽 弘充; 稲垣 光裕; 柳田 尚之; 芝木 泰一郎; 正村 裕紀; 工藤 岳秋; 庄中 達也; 折茂 達也; 及川 太
    北海道外科雑誌, 56, 2, 164, 165, 北海道外科学会, 2011年12月
    日本語
  • 脾彎曲部結腸癌に対する腹腔鏡下大腸切除術の検討
    工藤 岳秋; 中野 詩朗; 稲垣 光裕; 赤羽 弘充; 柳田 尚之; 正村 裕紀; 庄中 達也; 折茂 達也; 及川 太; 相山 健; 芝木 泰一郎
    日本内視鏡外科学会雑誌, 16, 7, 531, 531, (一社)日本内視鏡外科学会, 2011年12月
    日本語
  • EMR後局所再発に対し手術後3ヵ月で肝転移を来したAFP産生胃癌の1例
    折茂 達也; 中野 詩朗; 稲垣 光裕; 赤羽 弘充; 柳田 尚之; 芝木 泰一郎; 正村 裕紀; 工藤 岳秋; 庄中 達也; 及川 太; 相山 健
    癌と化学療法, 38, 12, 2328, 2330, (株)癌と化学療法社, 2011年11月
    日本語
  • [Two cases of neuroendocrine carcinoma of the rectum].
    Hiroki Shomura; Shirou Nakano; Hiromitsu Akabane; Mitsuhiro Inagaki; Naoyuki Yanagida; Taiichirou Shibaki; Takeaki Kudo; Tatsuya Shonaka; Tatsuya Orimo; Futoshi Oikawa; Takeshi Aiyama
    Gan to kagaku ryoho. Cancer & chemotherapy, 38, 12, 2265, 7, 2011年11月, ［国内誌］
    日本語, 研究論文（学術雑誌）, We report two cases of neuroendocrine carcinoma of the rectum. CASE 1: A 50s woman was diagnosed as rectal cancer and underwent anterior resection of the rectum and lymphnode dissection. The histological diagnosis was neuroendocrine carcinoma with peritoneal dissemination. She was treated with chemotherapy as an outpatient. One year later from the operation, multiple liver metastases were revealed and she died eight months later. CASE 2: A 50s man underwent endoscopic mucosal resection (EMR) of the rectum as rectal tumor and histological diagnosis was an early well-moderate deferenciated carcinoma and its cut-tend was unclear. He received a careful follow-up. One year later, a follow-up colonoscopy revealed a submucosal tumor in the lower rectum. He was diagnosised with local reccurence of rectal cancer, and then underwent an abdominoperineal resection of the rectum and lymphnode dissection. The histological diagnosis was poorly differenciated neuroendocrine carcinoma with lymphnode metastasis. Two months later from the operation, a local reccurence was revealed and he was treated with octreotide and irradiation.
  • [A case of AFP-producing gastric cancer patient with liver relapse occurred three months after endoscopic mucosal resection (EMR) and gastrectomy].
    Tatsuya Orimo; Shirou Nakano; Mitsuhiro Inagaki; Hiromitsu Akabane; Naoyuki Yanagida; Taiichirou Shibaki; Hiroki Shomura; Takeaki Kudo; Tatsuya Shonaka; Futoshi Oikawa; Takeshi Aiyama
    Gan to kagaku ryoho. Cancer & chemotherapy, 38, 12, 2328, 30, 2011年11月, ［国内誌］
    日本語, 研究論文（学術雑誌）, A 60s male was admitted to our hospital for a diagnosis of gastric tumor sized 20 mm in diameter at the fornix of the stomach. Endoscopic mucosal resection (EMR) was performed, and the resected tumor was pap, m, ly0, v0, HMX, VM0, pathologically. One month after the EMR, the local recurrence was confirmed and a partial gastrectomy was performed. Pathological findings were tub1, sm2, ly1, v1, HM0, VM0. Total gastrectomy was added because of the possibility of the lymph node metastasis. Pathological findings revealed no residual cancers. The final pathological diagnosis was T1b(sm2) N0H0P0M0, Stage IA, based on the Japanese classification of gastric cancer. Three months thereafter, CT showed multiple liver metastases. Immunohistochemical study of the operated tumor revealed AFP-producing gastric cancer. Chemotherapy was performed, but he died of the gastric cancer. Endoscopic treatment is a minimally invasive therapeutic strategy, but it requires a considerable care in application.
  • PPPDを施行したCircumportal pancreasの1例
    庄中 達也; 稲垣 光裕; 中野 詩朗; 赤羽 弘充; 柳田 尚之; 芝木 泰一郎; 正村 裕紀; 工藤 岳秋; 折茂 達也; 及川 太; 相山 健
    日本臨床外科学会雑誌, 72, 10, 2741, 2742, 日本臨床外科学会, 2011年10月
    日本語
  • 局所進行大腸癌におけるFOLFOX(XELOX)・FOLFIRIの術前化学療法としての検討
    正村 裕紀; 中野 詩朗; 赤羽 弘充; 稲垣 光裕; 柳田 尚之; 芝木 泰一郎; 工藤 岳秋; 庄中 達也; 折茂 達也; 及川 太; 相山 健
    日本癌治療学会誌, 46, 2, 826, 826, (一社)日本癌治療学会, 2011年09月
    日本語
  • 大腸癌肝転移切除例の治療成績
    横尾 英樹; 神山 俊哉; 中西 一彰; 柿坂 達彦; 田原 宗徳; 小丹枝 裕二; 相山 健; 蒲池 浩文; 松下 通明; 藤堂 省
    北海道外科雑誌, 56, 1, 59, 59, 北海道外科学会, 2011年06月
    日本語
  • 大腸穿通により診断に苦慮した肝エキノコックス症の一例
    相山 健; 神山 俊哉; 中西 一彰; 蒲池 浩文; 横尾 英樹; 田原 宗徳; 柿坂 達彦; 松下 通明; 藤堂 省
    北海道外科雑誌, 56, 1, 60, 60, 北海道外科学会, 2011年06月
    日本語
  • 巨大脾腫を伴う肝硬変合併肝細胞癌に対し脾摘を併施し治療した症例の検討
    相山健; 神山俊哉; 中西一彰; 横尾英樹; 谷口雅彦; 福森大介; 田原宗徳; 柿坂達也; 蒲池浩文; 松下通明; 藤堂省
    癌と化学療法, 37, 12, 2683, 2686, 2010年12月, ［査読有り］, ［筆頭著者］
    日本語, 研究論文（学術雑誌）

    ダウンロード
  • 有効肝切除率70%以上の大量肝切除における経皮経肝門脈塞栓術(PTPE)の有用性
    相山 健; 神山 俊哉; 福森 大介; 中西 一彰; 蒲池 浩文; 横尾 英樹; 田原 宗徳; 松下 通明; 藤堂 省
    IVR: Interventional Radiology, 25, 4, 557, 557, (一社)日本インターベンショナルラジオロジー学会, 2010年10月
    日本語
  • 原発巣切除から２５年後に多発肝転移をきたした顎下腺癌の１例
    相山 健; 松下 通明; 神山 俊哉; 中西 一彰; 横尾 英樹; 藤堂 省
    日本臨床外科学会雑誌, 71, 11, 2795, 2800, 日本臨床外科学会, 2010年, ［査読有り］, ［筆頭著者］
    日本語, 研究論文（学術雑誌）

    ダウンロード
  • 胆管内腫瘍栓により閉塞性黄疸を来した肝細胞癌の2例
    江本 慎; 神山 俊哉; 中西 一彰; 横尾 英樹; 田原 宗徳; 福森 大介; 川村 典生; 相山 健; 蒲池 浩文; 松下 通明; 藤堂 省
    日本臨床外科学会雑誌, 70, 8, 2570, 2570, 日本臨床外科学会, 2009年08月
    日本語
  • 肝細胞癌合併肝硬変に対する脾摘術の6例
    相山 健; 神山 俊哉; 中西 一彰; 横尾 英樹; 福森 大介; 田原 宗徳; 蒲池 浩文; 松下 通明; 藤堂 省
    日本臨床外科学会雑誌, 70, 8, 2571, 2571, 日本臨床外科学会, 2009年08月
    日本語
  • 切除後6年で孤立性肺転移を来した膵管癌の1例
    江本 慎; 蒲池 浩文; 田原 宗徳; 福森 大介; 川村 典生; 相山 健; 横尾 英樹; 中西 一彰; 神山 俊哉; 松下 通明; 藤堂 省
    北海道外科雑誌, 53, 2, 222, 223, 北海道外科学会, 2008年12月
    日本語
■ その他活動・業績
■ 主な担当授業
  • 基本医学研究, 2024年, 修士課程, 医学院
  • 基本医学総論, 2024年, 修士課程, 医学院
  • 医学総論, 2024年, 博士後期課程, 医学院
  • 基盤医学研究, 2024年, 博士後期課程, 医学院
  • 臨床医学研究, 2024年, 博士後期課程, 医学院
■ 共同研究・競争的資金等の研究課題